Pfizer yana la'akari da kashi na uku kuma Moderna yana la'akari da masu haɓakawa ko rigakafin farko don yaƙar bambance-bambancen juriya.

Pfizer da BioNTech sun sanar da fara a nazarin don kimanta aminci da immunogenicity (ikon haifar da amsawar rigakafi) na a kashi na uku na maganin alurar riga kafi a matsayin ƙarfafawa a kan sabbin bambance-bambancen coronavirus.

Binciken zai dogara ne akan mahalarta a cikin nazarin lokaci na 1 na maganin rigakafi a Amurka, waɗanda za a ba su damar samun 30 ug mai ƙarfafa rigakafin rigakafin da aka riga aka amince da shi tsakanin watanni 6 zuwa 12 bayan sun karɓi tsarin farko na kashi biyu.

A gefe guda, don "shirya don duk wani sauye-sauye masu yuwuwa a nan gaba," Pfizer da BioNTech sun sanar da cewa suna "ci gaba da tattaunawa" tare da hukumomin da suka dace, gami da Hukumar Abinci da Magunguna ta Amurka (FDA). , ga gajartar sa a cikin Ingilishi) da Hukumar Kula da Magunguna ta Turai (EMA, don gajarta a Turanci), zuwa gwajin, a cikin wannan binciken, wani gyare-gyaren rigakafin rigakafi daga bambance-bambancen 'B.1.351', wanda aka gano a Afirka ta Kudu.

Wannan na iya ba da damar kamfanoni sabunta maganin na yanzu cikin sauri idan buƙatar ta taso don kariya daga sabbin bambance-bambancen SARS-CoV-2. Don haka, kamfanonin suna fatan za su iya tabbatar da waɗannan yuwuwar rigakafin rigakafin nan gaba tare da tsari mai kama da abin da ke akwai na rigakafin mura, waɗanda ake sabunta kowace shekara. “Sassaushiyar dandamalin rigakafinmu yana ba mu damar haɓaka alluran rigakafin a cikin makwanni kaɗan, idan ya cancanta. An riga an kafa wannan hanyar ka'ida don sauran cututtuka masu yaduwa kamar mura, "in ji Shugaba kuma wanda ya kafa BioNTech, Ugur Sahin.

"Ko da ba mu ga wata shaida cewa bambance-bambancen suna haifar da asarar kariya ba allurar rigakafinmu ta samar, muna shan da yawa matakan aiwatar da yanke hukunci kuma a shirya idan nau'in ya zama mai juriya ga kariyar da allurar ta bayar. Wannan binciken ƙarfafawa yana da mahimmanci don fahimtar amincin kashi na uku da rigakafi daga nau'ikan yawo. A lokaci guda, muna yin hannun jarin da ya dace da kuma yin tattaunawa da masu gudanarwa don taimakawa kanmu don haɓakawa da neman izinin sabunta ko inganta rigakafin idan ya cancanta, "in ji Shugaban Pfizer kuma Shugaba Albert Bourla.

A irin wannan yanayin. Moderna ya sanar da cewa ya kammala ƙera kayan don ku 'Dan takarar rigakafin cutar coronavirus 'B.1.351, wanda aka fara gano shi a Afirka ta Kudu, kuma ya aika allurai zuwa Cibiyar Kiwon Lafiya ta Amurka (NIH) don gwajin asibiti na Mataki na 1.

Moderna yana nema dabaru guda biyu a kan waɗannan bambance-bambancen: da farko, kamfanin yana kimantawa kara kuzari na maganin alurar rigakafi don ƙara haɓaka rigakafi daga waɗannan nau'ikan. Na biyu, kamfanin yana shirin tantance riga-kafin riga-kafi da aka amince da shi da na bambance-bambancen Afirka ta Kudu kamar jerin alurar riga kafi na farko ga mutanen seronegative. Za a kimanta waɗannan 'yan takarar a cikin jerin kashi biyu a matakin kashi 100 ug da ƙasa.

Labarin da EM ya shirya bisa bayanin da Europa Press ya bayar